Tenosynovial Giant Cell Tumor Market Players:
- Abbisko Therapeutics
- Company Overview
- Business Planning
- Main Product Offerings
- Financial Execution
- Main Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Ammax Bio Inc.
- HUTCHMED
- SynOx Therapeutics Limited
- Deciphera Pharmaceuticals Inc.
- F. Hoffmann-La Roche Ltd
- Novartis AG
- Amgen Inc.
- Celleron Therapeutics Limited
- Takeda Pharmaceutical Company Limited.
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2026, the industry size of tenosynovial giant cell tumor is estimated at USD 1.05 billion.
The global tenosynovial giant cell tumor market size was more than USD 967.68 million in 2025 and is anticipated to grow at a CAGR of more than 9.4%, reaching USD 2.38 billion revenue by 2035.
North America’s tenosynovial giant cell tumor market will secure around 43% share by 2035, driven by the approval of novel drugs for tenosynovial giant cell tumors.
Key players in the market include Abbisko Therapeutics, Ammax Bio Inc., HUTCHMED, SynOx Therapeutics Limited, Deciphera Pharmaceuticals Inc., F. Hoffmann-La Roche Ltd., Novartis AG, Amgen Inc., Celleron Therapeutics Limited, Takeda Pharmaceutical Company Limited., Daiichi Sankyo Company, Limited., Chugai Pharmaceutical Co., Ltd., CHEPLAPHARM Arzneimittel GmbH, Ono Pharmaceutical Co., Ltd.
